title: Posttransplant De Novo Hepatitis C Virus Infection in Renal Transplant Recipients: Its Impact on Morbidity and Mortality.
abstract: OBJECTIVE
  The clinical effects of hepatitis C virus infection acquired after transplant have not been thoroughly studied. We aimed to study hepatitis C virus-related morbidity and mortality with de novo hepatitis C virus infection after renal transplant.
  
  
  METHODS
  Data from mortality files were retrospectively collected from January 2011 to January 2015. Patients were divided into 2 groups: hepatitis C virus positive (group A) and hepatitis C virus negative (group B).
  
  
  RESULTS
  Eighty-one patients were included, with median duration of survival of 39 months after transplant. In group A (32 patients), 78.1% of patients were males, with mean age of 36.83 ± 9.15 years. The mean survival duration was better in group A than in group B (67.59 ± 67.1 vs 58.10 ± 59.6 mo; P = .58). Acute cellular rejection was 25% in group A versus 20.4% in group B, whereas chronic allograft nephropathy was 20.4% for group A versus 18.4% for group B. Hepatitis C virus-related death was observed in 7 patients (21.9%). Infection was the main cause of death, with 40.6% of patients in group A versus 53% of patients in group B. On multivariate analyses, better patient survival was associated with greater interval of acquiring HCV after transplant (P = .038).
  
  
  CONCLUSIONS
  HCV infection acquired after renal transplant is not associated with increased HCV-related mortality, and prognosis is related to the time interval of acquiring infection after transplant.
authors.affiliation: From the Department of Hepatogastroenterology, Sindh Institute of Urology and Transplantation, Karachi, Pakistan.
authors.forename: Farina M
authors.initials: FM
authors.lastname: Hanif
authors.forename: S Muddasir
authors.initials: SM
authors.lastname: Laeeq
authors.forename: Nasir Hassan
authors.initials: NH
authors.lastname: Luck
authors.forename: Tahir
authors.initials: T
authors.lastname: Aziz
authors.forename: Zaigham
authors.initials: Z
authors.lastname: Abbas
authors.forename: Muhammed
authors.initials: M
authors.lastname: Mubarak
mesh_terms: D000328:Adult; D016009:Chi-Square Distribution; D005260:Female; D006084:Graft Rejection / Q000276:immunology / Q000821:virology; D006085:Graft Survival; D016174:Hepacivirus / Q000276:immunology / Q000472:pathogenicity*; D019698:Hepatitis C, Chronic / Q000175:diagnosis / Q000276:immunology / Q000401:mortality*; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000009:adverse effects; D016030:Kidney Transplantation / Q000009:adverse effects / Q000401:mortality*; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D012189:Retrospective Studies; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents